SDZ ICT 322
Alternative Names: SDZ 214322Latest Information Update: 03 Feb 1997
Price :
$50 *
At a glance
- Originator Novartis
- Class Antiemetics
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 03 Feb 1997 No-Development-Reported for Emesis in Switzerland (Unknown route)